Acrometa Group to Divest Its Life Sciences Business, Pursue New Business Opportunities in the Region
Oct 21, 2024 22:50 HKT |  |
|
康哲藥業入選2024年度「中國醫藥上市公司ESG競爭力」系列榜單
Oct 21, 2024 19:18 HKT | |
|
Everest Medicines Announces Taiwan TFDA Approval of NEFECON for the Treatment of Primary IgA Nephropathy
Oct 21, 2024 12:19 HKT | |
|
云顶新耀宣布中国台湾地区药政部门批准全球首个对因治疗IgA肾病药物耐赋康®的新药上市许可申请
Oct 21, 2024 12:08 HKT | |
|
雲頂新耀宣佈中國台灣地區藥政部門批准全球首個對因治療IgA腎病藥物耐賦康®的新藥上市許可申請
Oct 21, 2024 11:44 HKT | |
|
Everest Medicines' Stock Price Rises by 20% as Profit Potential Drives Valuation Recovery
Oct 18, 2024 18:37 HKT | |
|
云顶新耀股价升两成 盈利潜力助力估值修复
Oct 18, 2024 18:31 HKT | |
|
雲頂新耀股價升兩成 盈利潛力助力估值修復
Oct 18, 2024 18:28 HKT | |
|
康哲藥業：蘆可替尼乳膏（白癜風）大灣區首批處方落地
Oct 18, 2024 14:54 HKT |  |
|
Athos Announces Positive Topline Phase 1 Data for its AI-Generated, Novel, Oral G9A Inhibitor ATH-063, Demonstrating Selective Expansion and Activation of Potent Anti-Inflammatory Regulatory T Cells
Oct 17, 2024 08:00 HKT |  |
|
Athos宣布其人工智能生成的全新口服G9A抑制剂ATH-063的I期临床试验顶线数据，显示其对强效抗炎调节性T细胞的选择性扩增和激活
Oct 17, 2024 08:00 HKT | |
|
Athos宣佈其人工智慧生成的全新口服G9A抑製劑ATH-063的I期臨床試驗頂線數據，顯示其對強效抗炎調節性T細胞的選擇性擴增和啟動
Oct 17, 2024 08:00 HKT | |
|
CanSino Receives Another Strong Boost
Oct 09, 2024 19:29 HKT | |
|
GEN Announces Positive Phase 2 Clinical Trial Results for GN-037 Topical Cream in Patients With Mild to Moderate Plaque Psoriasis
Sep 25, 2024 21:00 HKT |  |
|
康哲藥業：磷酸蘆可替尼乳膏（白癜風）中國上市許可申請已獲受理
Sep 24, 2024 21:46 HKT | |
|
Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management
Sep 17, 2024 20:30 HKT |  |
|
君聖泰醫藥亮相香港國際生物科技論壇
Sep 17, 2024 15:00 HKT |  |
|
君聖泰醫藥亮相香港國際生物科技論壇
Sep 16, 2024 14:53 HKT | |
|
君圣泰医药亮相香港国际生物科技论坛
Sep 13, 2024 18:22 HKT | |
|
EASD 2024 | 君圣泰医药口头报告熊去氧胆小檗碱（HTD1801）在T2DM中的两项事后分析
Sep 11, 2024 11:51 HKT | |
|